Related Experiment Video
Updated: Aug 14, 2026

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia
Published on: December 22, 2023
Arrhythmogenic right ventricular dysplasia/cardiomyopathy
Kalpana R Prakasa1, Hugh Calkins
1Carnegie 592, Johns Hopkins Hospital, 600, N. Wolfe Street, Baltimore, MD 21287, USA.
Insights
Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) diagnosis relies on established criteria, not solely MRI. Early identification and ICD implantation are crucial for managing ventricular arrhythmias and preventing sudden death in ARVD/C patients.
Area of Science:
- Cardiology
- Genetics
- Medical Diagnostics
Background:
- Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is a genetic heart condition causing ventricular arrhythmias and right ventricular dysfunction.
- Accurate diagnosis is paramount for effective ARVD/C management.
- Current diagnostic practices may overemphasize MRI, neglecting established International Task Force criteria.
Purpose of the Study:
- To highlight the importance of International Task Force criteria for diagnosing ARVD/C.
- To emphasize the typical noninvasive and invasive diagnostic findings in ARVD/C.
- To guide treatment decisions, including ICD implantation and genetic screening.
Main Methods:
- Review of diagnostic criteria for ARVD/C.
- Discussion of noninvasive tests (ECG, echocardiogram) and invasive tests (RV angiogram, biopsy, EP study).
- Consideration of implantable cardioverter-defibrillator (ICD) indications and pharmacologic treatments (beta-blockers, ACE inhibitors).
- Emphasis on genetic screening for plakophilin-2 mutations.
Main Results:
- ARVD/C diagnosis requires adherence to International Task Force criteria.
- Patients typically present with abnormal ECG, echocardiogram, and ventricular arrhythmias.
- Invasive testing is recommended when noninvasive findings are suggestive.
- ICDs are indicated for syncope, sudden death, sustained ventricular arrhythmias, or specific ARVD/C evidence.
- Beta blockers and ACE inhibitors are recommended treatments.
- Plakophilin-2 mutation screening is beneficial for diagnosis and family management.
Conclusions:
- Correct diagnosis of ARVD/C hinges on International Task Force criteria.
- A comprehensive approach combining noninvasive, invasive, and genetic testing is essential.
- Timely ICD implantation and appropriate medical therapy improve outcomes for ARVD/C patients.
Abstract:
Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is a genetic cardiomyopathy characterized by ventricular arrhythmias and structural abnormalities of the right ventricle (RV). The most important aspect in the treatment of ARVD/C is establishing a correct diagnosis based on the International Task Force criteria. In our experience, cardiologists are not aware of these diagnostic criteria for ARVD/C and place too much importance on the results of magnetic resonance imaging of the RV. Patients with ARVD/C generally all have an abnormal 12-lead electrocardiogram, abnormal echocardiogram, and ventricular arrhythmias with a left bundle branch block morphology. If noninvasive testing suggests ARVD, invasive testing with an RV angiogram, RV biopsy, and electrophysiology study are recommended. We encourage patients to participate in the National Institutes of Health-sponsored multicenter clinical trial of ARVD/C (http://www.ARVD.comorhttp://www.ARVD.org). Once a diagnosis of ARVD/C is established, the main treatment decision involves whether to implant an implantable cardioverter-defibrillator (ICD). ICDs are recommended for patients who have experienced syncope, sudden death, or a sustained ventricular arrhythmia, and also for patients with overt evidence of ARVD, particularly if the electrophysiology study is abnormal or there is a family history of sudden death. We also recommend treatment of patients with ARVD/C with beta blockers and angiotensin-converting enzyme inhibitors, and that all patients with ARVD/C be screened for a mutation in the gene for plakophilin-2, because this is present in more than one third of patients with ARVD/C and may be helpful in the management of first-degree relatives.
Related Concept Videos
Cardiomyopathy I: Introduction and Classification
Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
Cardiomyopathy III: Hypertrophic Cardiomyopathy
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Cardiomyopathy IV: Restrictive Cardiomyopathy
Dysrhythmias III: Characteristics of Dysrhythmias

